EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Real‐world effectiveness of ustekinumab and vedolizumab in TNF‐exposed pediatric patients with ulcerative colitis

Perseus V Patel, Amy Zhang, Balu Bhasuran, Vignesh G Ravindranath, Melvin B Heyman, Sofia G Verstraete, Atul J Butte, Michael J Rosen, Vivek A Rudrapatna, ImproveCareNow Pediatric IBD Learning Health System

Journal of Pediatric Gastroenterology and Nutrition · 2024-05 · 78 (5) · 1126-1134

DOI: 10.1002/jpn3.12169 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 14.03.2024. Verfasst von Perseus V Patel und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of California San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Ustekinumab, Antibodies, Monoclonal, Humanized, Gastrointestinal Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NLM NIH HHS, NIDDK NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Vedolizumab (VDZ) and ustekinumab (UST) are second‐line treatments in pediatric patients with ulcerative colitis (UC) refractory to antitumor necrosis factor (anti‐TNF) therapy. Pediatric studies comparing the effectiveness of these medications are lacking. Using a registry from ImproveCareNow (ICN), a global research network in pediatric inflammatory bowel disease, we compared the effectiveness of UST and VDZ in anti‐TNF refractory UC.

Methods

We performed a propensity‐score weighted regression analysis to compare corticosteroid‐free clinical remission (CFCR) at 6 months from starting second‐line therapy. Sensitivity analyses tested the robustness of our findings to different ways of handling missing outcome data. Secondary analyses evaluated alternative proxies of response and infection risk.

Results

Our cohort included 262 patients on VDZ and 74 patients on UST. At baseline, the two groups differed on their mean pediatric UC activity index (PUCAI) ( p = 0.03) but were otherwise similar. At Month 6, 28.3% of patients on VDZ and 25.8% of those on UST achieved CFCR ( p = 0.76). Our primary model showed no difference in CFCR (odds ratio: 0.81; 95% confidence interval [CI]: 0.41–1.59) ( p = 0.54). The time to biologic discontinuation was similar in both groups (hazard ratio: 1.26; 95% CI: 0.76–2.08) ( p = 0.36), with the reference group being VDZ, and we found no differences in clinical response, growth parameters, hospitalizations, surgeries, infections, or malignancy risk. Sensitivity analyses supported these findings of similar effectiveness.

Conclusions

UST and VDZ are similarly effective for inducing clinical remission in anti‐TNF refractory UC in pediatric patients. Providers should consider safety, tolerability, cost, and comorbidities when deciding between these therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeUstekinumabAntibodies, Monoclonal, HumanizedGastrointestinal AgentsHumansFemaleMaleChildAdolescentTreatment OutcomeTumor Necrosis Factor-alphaRemission InductionPropensity ScoreRegistries

Stichwörter der Autor:innen

biologic therapychildrenclinical data sciencecomparative effectivenessinflammatory bowel disease

Substanzen

vedolizumabUstekinumabAntibodies, Monoclonal, HumanizedGastrointestinal AgentsTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Department of Pediatrics, University of California San Francisco, San Francisco, California, USA.
  • Division of Pediatric Gastroenterology, Stanford University School of Medicine, Palo Alto, California, USA.
  • Quantitative Sciences Unit, Stanford University School of Medicine, Palo Alto, California, USA.
  • Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, California, USA.
  • Department of Medicine, Division of Gastroenterology, University of California San Francisco, San Francisco, California, USA.

Förderung

  • NLM NIH HHS
  • NIDDK NIH HHS
  • NCATS NIH HHS
  • NIH HHS

Zitieren

APA

Patel, P. V., Zhang, A., Bhasuran, B., Ravindranath, V. G., Heyman, M. B., Verstraete, S. G., Butte, A. J., Rosen, M. J., Rudrapatna, V. A., & ImproveCareNow Pediatric IBD Learning Health System (2024). Real‐world effectiveness of ustekinumab and vedolizumab in TNF‐exposed pediatric patients with ulcerative colitis. Journal of Pediatric Gastroenterology and Nutrition, 78(5), 1126-1134. https://doi.org/10.1002/jpn3.12169

Vancouver

Patel PV, Zhang A, Bhasuran B, Ravindranath VG, Heyman MB, Verstraete SG, et al. Real‐world effectiveness of ustekinumab and vedolizumab in TNF‐exposed pediatric patients with ulcerative colitis. Journal of Pediatric Gastroenterology and Nutrition. 2024;78(5):1126-1134. doi:10.1002/jpn3.12169

BibTeX
@article{Patel2024,
  author = {Patel, Perseus V and Zhang, Amy and Bhasuran, Balu and Ravindranath, Vignesh G and Heyman, Melvin B and Verstraete, Sofia G and Butte, Atul J and Rosen, Michael J and Rudrapatna, Vivek A and ImproveCareNow Pediatric IBD Learning Health System, ImproveCareNow Pediatric IBD Learning Health System},
  title = {Real‐world effectiveness of ustekinumab and vedolizumab in TNF‐exposed pediatric patients with ulcerative colitis},
  journal = {Journal of Pediatric Gastroenterology and Nutrition},
  year = {2024},
  volume = {78},
  number = {5},
  pages = {1126--1134},
  doi = {10.1002/jpn3.12169}
}
Kostenlos starten →